Clinical trial
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
NCT00423332 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00423332 |
|---|---|
| Title | Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma |
| Official title | A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib 45mg Versus Placebo Following 12 Weeks of Treatment in Patients With Metastatic or Recurrent Renal Cell Carcinoma Who Have Had no Previous Anti-VEGF Therapy. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Cediranib, Cediranib Placebo |
| Enrollment | 105 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Oct 1, 2016 |
| First posted | Jan 18, 2007 |
| Last update posted | Feb 2, 2017 |
| Countries | Netherlands, United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: